跳至主要内容
临床试验/ACTRN12613000465752
ACTRN12613000465752尚未招募1 期

A study evaluating the effects of Apolipoprotein E driven therapeutics for Alzheimer’s disease

uclear Medicine and Centre for PET Research Fund0 个研究点目标入组 20 人开始时间: 2013年4月24日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
50 Years 至 o limit(—)
性别
All

入选标准

  • Completion of the standard evaluation and fulfillment of the specific diagnostic criteria for very early Alzheimer's Disaease and mild Alzheimer's Disease. Also to be fluent in English; Age >50; >7 years of education; adequate visual and auditory acuity to complete neuropsychological testing;to have a reliable caregiver who is able to provide accurate information about the patient’s symptoms;

排除标准

  • A negative brain PET scan;a lifetime history of schizophrenia, schizoaffective disorder, or treatment with ECT;recent history of drug or alcohol abuse/dependence;
  • any significant disease or unstable medical condition that in the opinion of the investigators, could affect drug levels or neuropsychological testing.

研究者

发起方
uclear Medicine and Centre for PET Research Fund

相似试验